#None #CRISPR #Functional Genomics #IRBM

IRBM Enhances Its Functional Genomics Platform for Drug Discovery

IRBM, an integrated Contract Research Organization (CRO) specializing in preclinical drug discovery, has announced an expansion of its Functional Genomics Platform, aiming to enhance the identification and validation of genetic targets as well as the creation of disease-relevant cellular models. This comprehensive platform incorporates a blend of CRISPR-based methodologies, advanced screening capabilities, cellular technologies, and cutting-edge molecular and cellular analyses, streamlining both target discovery and validation processes.

Advancements in Genomic Targeting

To improve target validation, IRBM is augmenting its genome editing toolkit with cutting-edge CRISPR technologies. This includes CRISPR tiling, a method for systematically mapping functional domains within both coding and regulatory regions, alongside Base and Prime Editing for precise nucleotide modifications. These next-generation approaches, combined with high-throughput CRISPR screening, are crucial for developing robust disease models and ensuring the reliability of target validation.

Dr. Sara Tomaselli, Head of Functional Genomics at IRBM, stated, "Understanding which targets are genuinely achievable for drug development is a complex challenge. With this internal platform, we are strengthening our ability to systematically evaluate gene function, mitigate risks in early discovery, and assist our partners in making informed decisions."

The platform's screening functionalities include genome-wide and targeted CRISPR libraries for Knockout (CRISPR KO), Inhibition (CRISPRi), and Activation (CRISPRa), allowing for an in-depth exploration of gene function and associated signaling pathways. Concurrently, IRBM's expertise in cell technologies—including patient-relevant models and systems derived from induced pluripotent stem cells (iPSCs)—supports disease modeling in oncology, neurodegeneration, and rare diseases.

Integrating Multidisciplinary Insights

One of the key innovations of the IRBM Functional Genomics Platform is the integration of multi-omics approaches. This encompasses high-content imaging, single-cell transcriptomics, and proteomics, facilitating deeper functional characterization of drug targets. The platform is part of a broader, fully integrated ecosystem for drug discovery, ensuring that genetic insights translate into meaningful preclinical models and drug development strategies.

By merging functional genomics with expertise in medicinal chemistry, biomarker discovery, and preclinical pharmacology, IRBM empowers biopharma innovators to approach target validation with greater confidence. Dr. Carlo Toniatti, Chief Scientific Officer at IRBM, elaborates: "We adopt a careful, methodical approach in functional genomics that aligns well with the complexities of drug research. Our aim is to assist our partners in identifying high-quality targets and generating data that can serve as a guide and informational resource throughout the drug discovery process."

Supporting Innovation in Drug Development

IRBM's collaborative methodology allows biotech start-ups, pharmaceutical firms, and venture capital-funded teams to access functional genomics expertise without the need for their own infrastructure. Providing tailored solutions that include genetic screenings, artificial cell models, and mechanistic studies, IRBM offers practical, scientifically informed support at critical junctures in the drug research lifecycle.

For more information on the Functional Genomics Platform at IRBM and collaboration opportunities, please visit www.irbm.com.

About IRBM

IRBM is a Contract Research Organization (CRO) focused on early-stage drug discovery. With a proven track record of delivering preclinical candidates in oncology, neurodegeneration, and infectious diseases, IRBM collaborates with innovative biotech and pharmaceutical companies to drive therapeutic development with scientific precision and transparency.